Written Question·Department of Health and Social Care·UIN 11055
Myasthenia Gravis: Drugs
Tabled: 24 October 2024
Answered: 29 October 2024
Named DayQuestion
Mr Richard Holden
Conservative — Basildon and Billericay
To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential merits of making (a) rozanolixizumab, (b) zilucoplan and (c) efgartigimod available to NHS patients with myasthenia gravis (MG); and w
Answer
Karin SmythThe Department has made no such assessment. The National Institute for Health and Care Excellence (NICE) makes evidence-based recommendations for the National Health Service on whether new medicines should be routinely funded by the NHS, based on an asses...
ⓘ
This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 11055) →